Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBG/CBD Oil for Chemotherapy-Induced Peripheral Neuropathy
NCT07016971Phase 1Recruiting
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- Apr 2026
- Primary completion
- Apr 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cannabigerol and cannabidiol in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by Penn State Health Milton S. Hershey Medical Center. Primary endpoints: Safety and Tolerability of CBG/CBD Oil at 12 weeks and Feasibility of Treatment with CBG/CBD Oil at 4 weeks. Started Apr 2026; status: recruiting.
02
Drugs
cannabigerolcannabidiol
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT07016971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07016971.